抗体バンク(東北大学・加藤研究室)

<
タグ関連抗体の説明実験対象文献販売
抗PAtag抗体
(NZ-1; rat IgG2a, lambda)
PAtagシステム(ペプチドタグシステム)に使用するモノクローナル抗体。PAtagは加藤研の登録商標です。(登録第5671624号) タンパク質精製、IP、IHC, WB, FACSなど、すべての実験に有用。タンパク質精製については、Fujii et al., PEP2014; Fujii et al., JCS2016の2報で詳述。さらに、蛋白質科学会アーカイブでプロトコールを解説。WBについては、複数の論文で使用例あり。 論文1
文献

和光
抗MAPtag抗体
(PMab-1;rat IgG2a, kappa)
MAPtagシステム(ペプチドタグシステム)に使用するモノクローナル抗体。 タンパク質精製、IP、IHC, WB, FACSなど、すべての実験に有用。WBについては、PAtagよりも感度が高い。flow cytometryにおいては、PAtag抗体は一部のヒト細胞株(293Tなど)に反応するが、MAPtag抗体はヒト細胞株に一切反応しないため、膜タンパク質の解析に威力を発揮する。タンパク質精製については、Fujii et al., MAB2016で詳述。 論文1
論文2
抗RAPtag抗体
(PMab-2;mouse IgG1, kappa)
RAPtagシステム(ペプチドタグシステム)に使用するモノクローナル抗体。 タンパク質精製、IP、IHC, WB, FACSなど、すべての実験に有用。 論文1
論文2
抗MBPtag抗体
(TMab-2;rat IgG2b, kappa)
maltose-binding proteinを特異的に認識。 IHC, WBなどの実験に有用。 論文
和光
ポドカリキシン関連抗体の説明実験対象文献販売
抗ヒトポドカリキシン抗体
(PcMab-47;mouse IgG1, kappa)
ヒトポドカリキシンを特異的に認識。 WB, IHC, FACSなど、すべての実験に有用。 論文
ATRX, TERT関連抗体の説明実験対象文献販売
抗ATRX抗体
(AMab-6;mouse IgG1, kappa)
ATRXを特異的に認識。 IHCに有用。 論文
和光
抗hTERT抗体
(TMab-6;mouse IgM, kappa)
hTERTを特異的に認識。 IHCに有用。 和光
ポドプラニン関連抗体の説明実験対象文献販売
抗マウスポドプラニン抗体
(PMab-1;rat IgG2a, kappa)
マウスポドプラニンに対する、高感度モノクローナル抗体。

マウスキメラ型抗体(mPMab-1)など、多数の改変抗体を作製済み。すべて、供与可能です。
IHC, WB, FACSなど、すべての実験に有用。 論文
和光
MBL
Thermo
フナコシ
Novus
抗ラットポドプラニン抗体
(PMab-2;mouse IgG1, kappa)
ラットポドプラニンに対する、高感度モノクローナル抗体。 IHC, WB, FACSなど、すべての実験に有用。 論文
和光
抗ウサギポドプラニン抗体
(PMab-32;mouse IgG1, kappa)
ウサギポドプラニンに対する、世界初のモノクローナル抗体。 IHC, WB, FACSなど、すべての実験に有用。 論文
和光
抗イヌポドプラニン抗体
(PMab-38;mouse IgG1, kappa)
イヌポドプラニンに対する、高感度モノクローナル抗体。 IHC, WB, FACSなど、すべての実験に有用。 論文
和光
抗ウシポドプラニン抗体
(PMab-44;mouse IgG1, kappa)
ウシポドプラニンに対する、高感度モノクローナル抗体。 IHC, WB, FACSなど、すべての実験に有用。 論文
ヒトポドプラニン関連抗体の説明実験対象文献販売
抗ヒトポドプラニン抗体
(NZ-1.2, NZ-1.3, NC-08)
ヒトキメラ型抗体(NZ-12)など、多数の改変抗体を作製済み。すべて、供与可能です。

NZ-1.2, NZ-1.3, NC-08などのクローンは、多くの論文で使われています。
タンパク質精製、IP、IHC, WB, FACSなど、すべての実験に有用。 Thermo
BioLegend
Sigma
Millipore
MBL
Novus
フナコシ
抗ヒトポドプラニン抗体
(LpMab-2;mouse IgG1, kappa)
CasMab IHC, WB, FACSなどの実験に有用。 論文
特許
抗ヒトポドプラニン抗体
(LpMab-3;mouse IgG1, kappa)
ヒトポドプラニンに対する、高感度モノクローナル抗体。Thr76を認識。 IHC, WB, FACSなど、すべての実験に有用。 論文
特許
抗ヒトポドプラニン抗体
(LpMab-7;mouse IgG1, kappa)
ヒトポドプラニンに対する、高感度モノクローナル抗体。 IHC, WB, FACSなど、すべての実験に有用。 論文
特許
抗ヒトポドプラニン抗体
(LpMab-9;mouse IgG1, kappa)
ヒトポドプラニンに対する、高感度モノクローナル抗体。Thr25を認識。 WB, FACSなどに有用。 論文
特許
抗ヒトポドプラニン抗体
(LpMab-10;mouse IgG3, kappa)
PLAG1のThr34を認識。 IHC, WB, FACSなど、すべての実験に有用。 論文
和光
抗ヒトポドプラニン抗体
(LpMab-12;mouse IgG1, kappa)
PLAG3のThr52に付加された糖鎖を認識。 IHC, WB, FACSなど、すべての実験に有用。 論文
和光
抗ヒトポドプラニン抗体
(LpMab-13;mouse IgG1, kappa)
PLAG2-3を認識。NZ-1抗体のエピトープと類似。 IHC, WB, FACSなど、すべての実験に有用。 論文
和光
抗ヒトポドプラニン抗体
(LpMab-17;mouse IgG1, kappa)
PLAG4を認識。 IHC, WB, FACSなど、すべての実験に有用。内在性のポドプラニンも高感度に認識します。 文献
BD
和光
ABM
抗ヒトポドプラニン抗体
(LpMab-19;mouse IgG2b, kappa)
ヒトポドプラニンに対する、高感度モノクローナル抗体。Thr76を認識。 IHC, WB, FACSなど、すべての実験に有用。ADCC/CDC活性あり。 論文
抗ヒトポドプラニン抗体
(LpMab-21;mouse IgG2a, kappa)
ヒトポドプラニンに対する、高感度モノクローナル抗体。Thr76を認識。 IHC, WB, FACSなど、すべての実験に有用。ADCC/CDC活性あり。 論文
ABM
抗ヒトポドプラニン抗体
(LpMab-23;mouse IgG1, kappa)
CasMab IHC, WB, FACSなどの実験に有用。 論文
特許
IDH関連抗体の説明実験対象文献販売
抗ヒトIDH1-R132H抗体
(HMab-1;mouse IgG1, kappa)
IDH1-R132Hを特異的に認識。 IHC, WBなどの実験に有用。(WHO2016で、R132Hに対するIHCが必須に。) 論文 和光
millipore
MBL
Sigma
IBL
抗ヒトIDH1-R132H抗体
(HMab-2;mouse IgG1, kappa)
IDH1-R132Hを特異的に認識。 IHC, WBなどの実験に有用。 論文 和光
抗ヒトIDH1-R132S抗体
(SMab-1;mouse IgG1, kappa)
IDH1-R132Sを特異的に認識。 IHC, WBなどの実験に有用。 論文 和光
millipore
MBL
IBL
Sigma
抗ヒトIDH1-R132G抗体
(GMab-r1;rat IgG2a, kappa)
IDH1-R132Gを特異的に認識。 IHC, WBなどの実験に有用。 論文 MBL
抗ヒトIDH2-R172K抗体
(KMab-1;rat IgG2b, kappa)
IDH2-R172Kを特異的に認識。 IHC, WBなどの実験に有用。 論文 MBL
抗ヒトIDH2-R172M抗体
(MMab-1;rat IgG2b, kappa)
IDH2-R172Mを特異的に認識。 IHC, WBなどの実験に有用。 論文 MBL
抗ヒトIDH2-R172W抗体
(WMab-1;rat IgG2b, kappa)
IDH2-R172Wを特異的に認識。 IHC, WBなどの実験に有用。 論文 MBL
抗ヒトIDH1抗体
(RMab-3;mouse IgG1, kappa)
IDH1を特異的に認識。 IHC, WBなどの実験に有用。 論文 和光
MBL
抗ヒトIDH1抗体
(RcMab-1;rat IgG2a, kappa)
IDH1を特異的に認識。 IHC, WBなどの実験に有用。 論文 和光
MBL
抗ヒトIDH2抗体
(RMab-22;mouse IgG2b, kappa)
IDH1を特異的に認識。 IHC, WBなどの実験に有用。 論文 和光
MBL
抗ヒトIDH2抗体
(KrMab-3;mouse IgG1, kappa)
IDH1を特異的に認識。 IHC, WBなどの実験に有用。 論文 MBL
抗変異型IDH1/2抗体
(MsMab-1;mouse IgG1, kappa)
IDH1を特異的に認識。 IHC, WBなどの実験に有用。 論文 和光
MBL
抗変異型IDH1/2抗体
(MsMab-2;rat IgG2a, kappa)
IDH1を特異的に認識。 IHC, WBなどの実験に有用。 論文
本抗体バンクは、AMED創薬等支援技術基盤プラットフォーム(平成24年度〜28年度)およびAMED創薬ライフサイエンス研究支援基盤事業(平成29年度〜33年度)の成果です。上記のタグシステムや抗体は、簡単なMTA(AMED謝辞記載、再分譲不可、販売不可、など)を交わすことで無償で(タグ抗体のセファロースは1mlまで、各種抗体は100ugまで)供与可能です。分譲量が多い場合は、共同研究ベースとなります。ご希望の方は、下記にご連絡ください。
担当者連絡先:東北大学大学院医学系研究科抗体創薬研究分野 加藤 幸成
E-mail:yukinarikato@gmail.com
共同研究や分譲依頼が難しい場合は、様々な企業からの購入も可能です。(販売例:PA tag (和光純薬)抗ポドプラニン,モノクローナル抗体(和光純薬)神経膠腫の免疫組織化学用抗体(和光純薬)
細胞バンクもご覧下さい。


参考文献



*タグ関連

  • Fujii Y, Kaneko MK, Kato Y*.
    (*corresponding author)


    MAP tag: A novel tagging system for protein purification and detection.

    Monoclon. Antib. Immunodiagn. Immunother., DOI: 10.1089/mab.2016.0039, 2016 (PDF)
    PDIS


  • Fujii Y, Matsunaga Y, Arimori T, Kitago Y, Ogasawara S, Kaneko MK, Kato Y, Takagi J.

    Tailored placement of a turn-forming PA tag into the structured domain of a protein to probe its conformational state

    J Cell Sci,,29(7):1512-22, 2016(PDF)
    PDIS


  • Fujii Y, Kaneko M, Neyazaki M, Nogi T, Kato Y*, Takagi J*
    (*corresponding author)

    PA tag: a versatile protein tagging system using a super high affinity antibody against a dodecapeptide derived from human podoplanin.

    Protein Expr Purif. Volume 95, 240-247, 2014 (pdf)(大阪大学との共同研究@東北大学)PDIS






  • *ポドプラニン関連

  • Kato Y* and Kaneko MK.
    (*corresponding author)

    A Cancer-specific Monoclonal Antibody Recognizes the Aberrantly Glycosylated Podoplanin.

    Sci Rep 4, 5924, 2014(@東北大学)(注目の論文
    PDIS


  • Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M, Fujii Y, Ogasawara S, Kato Y*
    (*corresponding author)


    Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity

    Cancer Med., ,6(4): 768-777, 2017
     
  • Nagae M, Morita-Matsumoto K, Kato M, Kaneko MK, Kato Y, Yamaguchi Y.

    A novel platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and non-glycosylated rhodocytin.

    Structure, Volume 22, Issue 12, p1711?1721, 2 December 2014 (理研との共同研究@東北大学)
    PDIS


  • Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y*.
    (*corresponding author)


    Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas and TALEN

    Cancer Med., in press
    PDIS


  • Kato Y*, Kunita A, Fukayama M, Abe S, Nishioka Y, Uchida H, Tahara H, Yamada S, Yanaka M, Nakamura T, Saidoh N, Yoshida K, Fujii Y, Honma R, Takagi M, Ogasawara S, Murata T, Kaneko MK*
    (*corresponding author)


    Anti-Glycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin via Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity

    Monoclon. Antib. Immunodiagn. Immunother., in press


  • Kato Y*, Ogasawara S, Oki H, Goichberg P, Honma R, Fujii Y, Kaneko MK.
    (*corresponding author)


    LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-glycan on Thr52 of Platelet Aggregation-stimulating Domain of Human Podoplanin

    PLoS ONE,11(3): e0152912., 2016 (PDF)
    PDIS


  • Abe S, Kaneko MK, Tsuchihashi Y, Izumi T, Okada N, Miyamoto R, Sato C, Tobiume M, Otsuka K, Tsuchiya K, Kawazoe K, Ogasawara S, Kato Y, and Nishioka Y.

    Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in orthotopic xenograft model

    Cancer Sci.,107, 1198?1205, 2016(PDF)
    PDIS


  • Shiina S, Ohno M, Ohka F, Kuramitsu S, Yamamichi A, Kato A, Motomura K, Tanahashi K, Yamamoto T, Watanabe R, Ito I, Senga T, Hamaguchi M, Wakabayashi T, Kaneko MK, Kato Y, Chandramohan V, Bigner DD, Natsume A.

    CAR T cells targeting podoplanin reduce orthotopic glioblastomas in mouse brains

    Cancer Immunol Res.;4(3):259-68.,2016 (PDF)
    PDIS


  • Kato Y*, Vaidyanathan G, Kaneko MK, Mishima K, Srivastava N, Chandramohan V, Pegram C, Keir ST, Kuan CT, Bigner DD, Zalutsky MR.(*corresponding author)

    Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas

    Nuclear Medicine & Biology.,37(7), 785-794 ,2010 (pdf)(@Duke大学)


  • Chaipan C, Steffen I, Tsegaye TS, Bertram S, Glowacka I, Kato Y, Schmokel J, Munch J, Gerardy-Schahn R, and Pohlmann S.

    Incorporation of podoplanin into human immunodeficiency virus particles released from HEK-293T cells, but not PBMC, is required for efficient binding to the attachment factor CLEC-2 and transmission to target cells

    Retrovirology, 19;7(1):47, 2010 (PDF)


  • Kuno A, Kato Y (double first), Matsuda A, Kaneko MK, Ito H, Amano K, Chiba Y, Narimatsu H, Hirabayashi J.

    Focused differential glycan analysis with the platform antibody-assisted lectin profiling (ALP) for glycan-related biomarker verification.

    Molecular & Cellular Proteomics, 8:99-108, 2009. (PDF)


  • Nakazawa Y, Sato S, Naito M, Kato Y, Mishima K, Arai H, Tsuruo T, Fujita N.

    Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis.

    Blood, 112(5), 1730-1739, 2008 (PDF)


  • Amano K, Chiba Y, Kasahara Y, Kato Y, Kaneko MK, Kuno A, Ito H, Kobayashi K, Hirabayashi J, Jigami Y, Narimatsu H.

    Engineering of mucin-type human glycoproteins in yeast cells.

    Proc Natl Acad Sci U S A., 105, 3232-3237, 2008


  • Kato Y*, Kaneko MK, Kunita A, Ito H, Kameyama A, Ogasawara S, Matsuura N, Hasegawa Y, Suzuki-Inoue K, Inoue O, Ozaki Y and Narimatsu H.(*corresponding author)

    Molecular analysis of pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2.

    Cancer Sci, 99(1), 54-61,2008


  • Suzuki H, Kato Y* (double first), Kaneko MK, Okita Y, Narimatsu H, and Kato M.(*corresponding author)

    Induction of podoplanin by transforming growth factor-β in human fibrosarcoma.

    FEBS lett., 582, 341-345, 2008


  • Kaneko MK, Kato Y (double first), Kameyama A, Ito H, Kuno A, Hirabayashi J, Kubota T, Amano K, Chiba Y, Hasegawa Y, Sasagawa I, Mishima K, Narimatsu H.

    Functional glycosylation of human podoplanin: glycan structure of platelet aggregation-inducing factor.

    FEBS Lett., 581(2):331-336, 2007


  • Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, Yatomi Y, Narimatsu H, Ozaki Y.

    Involvement of the snake toxin receptor CLEC-2 in podoplanin-mediated platelet activation by cancer cells.

    J Biol Chem. 282(36):25993-26001, 2007


  • Kunita A., Kashima T., Morishita Y., Fukayama M., Kato Y., Tsuruo T., Fujita N.

    The platelet aggregation-inducing factor Aggrus/podoplanin promotes pulmonary metastasis.

    Am J Pathol., 170(4):1337-1347, 2007


  • Kato Y.*, Kaneko MK., Kuno A., Uchiyama N., Amano K., Chiba Y., Hasegawa Y., Hirabayashi J., Narimatsu H., Mishima K., Osawa M.(*corresponding author)

    Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet- aggregation-stimulating domain.

    Biochem Biophys Res Commun., 349(4):1301-1307, 2006


  • Kaneko MK, Kato Y, Kitano T, Osawa M.

    Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor.

    Gene, 378C:52-57, 2006


  • Mishima K, Kato Y*, Kaneko MK, Nishikawa R, Hirose T, Matsutani M.(*corresponding author)

    Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression.

    Acta Neuropathol (Berl).111(5):483-488, 2006


  • Mishima, K., Kato Y*, Kaneko, MK., Nakazawa, Y., Kunita, A., Fujita, N., Tsuruo, T., Nishikawa, R., Hirose, T., Matsutani, M.(*corresponding author)

    Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma.

    Acta Neuropathol (Berl). 111(6):563-568. 2006


  • Kato Y., Kaneko, M., Sata, M., Fujita, N., Tsuruo, T., Osawa, M.

    Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet aggregation-inducing factor in lung squamous cell carcinoma.

    Tumor Biol. 26 (4) 195-200, 2005


  • Kato Y., Sasagawa, I., Kaneko, M., Osawa, M., Fujita, N., Tsuruo, T.

    Aggrus: A diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors.

    Oncogene. 23, 8552-8556, 2004


  • Kaneko, M., Kato Y., Kunita, A., Fujita, N., Tsuruo, T., Osawa, M.

    Functional sialylated O-glycan to platelet aggregation on Aggrus (T1alpha/Podoplanin) molecules expressed in Chinese hamster ovary cells.

    J Biol. Chem. 279 ,38838-38843, 2004


  • Kato Y., Fujita, N., Kunita, A., Sato, S., Kaneko, M., Osawa, M. and Tsuruo, T.

    Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors.

    J Biol. Chem. 278, 51599-51605, 2003.


  • Ochoa-Alvarez JA, Krishnan H, Pastorino JG, Nevel E, Kephart D, Shen Y, Fatahzadeh M, Baredes S, Kalyoussef E, Honma M, Adelson ME, Kaneko MK, Kato Y, Yin K, Shienbaum AJ, Jensen LD, and Goldberg GS.

    Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms.

    Oncotarget,6(11),9045-9060,2015
    PDIS


  • Kaneko MK, Kunita A, Abe S, Tsujimoto Y, Fukayama M, Goto K, Sawa Y, Nishioka Y, Kato Y*.
    (*corresponding author)

    Chimeric anti-podoplanin antibody suppresses tumor metastasis via neutralization and antibody-dependent cellular cytotoxicity

    Cancer Sci., 103 (11), 1913?1919, 2012 (pdf)(東京大学との共同研究@山形大学)


  • Chiaki Kaji, Yuta Tsujimoto, Mika Kato Kaneko, Yukinari Kato*, and Yoshihiko Sawa*.
    (*corresponding author)

    Immunohistochemical Examination of Novel Rat Monoclonal Antibodies against Mouse and Human Podoplanin.

    Acta Histochm. Cytochem., 45 (4): 227-237, 2012 (pdf)(福岡歯科大学との共同研究@山形大学)


  • Hatakeyama K, Kaneko MK, Kato Y*, Ishikawa T, Nishihira K, Tsujimoto Y, Shibata Y, Ozaki Y, Asada Y.
    (*corresponding author)

    Podoplanin expression in advanced atherosclerotic lesions of human aortas

    Thromb. Res. 129: 70-76, 2012 (pdf)(宮崎大学との共同研究@山形大学)


  • Kaji C, Tomooka M, Kato Y, Kojima H, Sawa Y

    The expression of podoplanin and classical cadherins in the brain

    J Anat. ;220(5):435-46, 2012 (pdf)(福岡歯科大学との共同研究@山形大学) DOI: 10.1111/j.1469-7580.2012.01484.x


  • Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J, Sato S, Kishuku M, Taniguchi Y, Azuma M, Kawazoe K, Sekido Y, Yano S, Akiyama S, Sone S, Minakuchi K, Kato Y, Nishioka Y

    A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody.

    J. Immunol., 190(12):6239-49 (pdf)(徳島大学との共同研究@山形大学)PDIS


  • Chandramohan V, Bao X, Kaneko MK, Kato Y, Keir ST, Szafranski S, Kuan CT, Pastan I, Bigner DD.

    Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors

    Int. J. Cancer;132(10):2339-48, 2013 (pdf)(@Duke大学)


  • Maruyama Y, Maruyama K, Kato Y, Kajiya K, Moritoh S, Yamamoto K, Matsumoto Y, Kerjaschki D, Nakazawa T, Kinoshita S.

    The Effect of Podoplanin Inhibition on Lymphangiogenesis under Pathological Conditions.

    Invest Ophthalmol Vis Sci., 55:4813-4822; 2014(眼科との共同研究@東北大学)PDIS


  • Kato Y*, Kunita A, Abe S, Ogasawara S, Fujii Y, Oki H, Fukayama M, Nishioka Y, and Kaneko MK.
    (*corresponding author)


    The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.

    Oncotarget, 6(34): 36003-36018, 2015 (PDF)
    PDIS


  • Kaneko MK, Oki H, Hozumi Y, Liu X, Ogasawara S, Takagi M, Goto K, Kato Y*
    (*corresponding author)

    A monoclonal antibody LpMab-9 recognizes O-glycosylated N-terminus of human podoplanin.

    Monoclon. Antib. Immunodiagn. Immunother.,34(5): 310-317, 2015 (PDF)
    PDIS


  • Kaneko MK, Oki H, Ogasawara S, Takagi M, Kato Y*
    (*corresponding author)

    An anti-podoplanin monoclonal antibody LpMab-7 detects metastatic lesions of osteosarcoma

    Monoclon. Antib. Immunodiagn. Immunother., 34(3): 154-161, 2015 (PDF)
    PDIS


  • Ogasawara S, Oki H, Kaneko MK, Hozumi Y, Liu X, Honma R, Fujii Y, Nakamura T, Goto K, Takagi M, Kato Y*
    (*corresponding author)

    Development of a monoclonal antibody LpMab-10 recognizing non-glycosylated PLAG1/2 domain including Thr34 of human podoplanin.

    Monoclon. Antib. Immunodiagn. Immunother., 34(5): 318-326, 2015 (PDF)
    PDIS


  • Oki H, Honma R, Ogasawara S, Fujii Y, Liu X, Kaneko MK, Takagi M, Kato Y*
    (*corresponding author)

    Development of a sensitive monoclonal antibody PMab-2 against rat podoplanin

    Monoclon. Antib. Immunodiagn. Immunother., 34(6): 396-403, 2015 (PDF)
    PDIS


  • Oki H, Kaneko MK, Ogasawara S, Tsujimoto Y, Liu X, Sugawara M, Takakubo Y, Takagi M, Kato Y*
    (*corresponding author)

    Characterization of a monoclonal antibody LpMab-7 recognizing non-PLAG domain of podoplanin

    Monoclon. Antib. Immunodiagn. Immunother., 34(3): 174-180, 2015 (PDF)
    PDIS


  • Oki H, Ogasawara S, Kaneko MK, Takagi M, Yamauchi Y, Kato Y.*
    (*corresponding author)

    Characterization of a monoclonal antibody LpMab-3 recognizing sialylated glycopeptide of podoplanin.

    Monoclon. Antib. Immunodiagn. Immunother.,34(1): 44-50, 2015
    PDIS


  • Ogasawara S, Honma R, Kaneko MK, Fujii Y, Kagawa Y, Konnai S, Kato Y*
    (*corresponding author)


    Podoplanin Expression in Canine Melanoma

    Monoclon. Antib. Immunodiagn. Immunother., in press
    PDIS


  • Kaneko MK, Honma R, Ogasawara S, Fujii Y, Nakamura T, Saidoh N, Takagi M, Kagawa Y, Konnai S, Kato Y*.
    (*corresponding author)


    PMab-38 recognizes canine podoplanin of squamous cell carcinomas.

    Monoclon. Antib. Immunodiagn. Immunother., 35(5): 263-266, 2016 (PDF)
    PDIS


  • Ogasawara S, Kaneko MK, Kato Y*
    (*corresponding author)


    LpMab-19 Recognizes Sialylated O-glycan on Thr76 of Human Podoplanin

    Monoclon. Antib. Immunodiagn. Immunother.,35(5): 245-253, 2016 (PDF)
    PDIS


  • Honma R, Kaneko MK, Ogasawara S, Fujii Y, Konnai S, Takagi M, Kato Y*
    (*corresponding author)

    Specific Detection of Dog Podoplanin Expressed in Renal Glomerulus by A Novel Monoclonal Antibody PMab-38 in Immunohistochemistry.

    Monoclon. Antib. Immunodiagn. Immunother.,35(4): 212-216, 2016 (PDF)
    PDIS


  • Honma R, Ogasawara S, Kaneko MK, Fujii Y, Oki H, Nakamura T, Takagi M, Konnai S, Kato Y * (*corresponding author)

    PMab-44 Detects Bovine Podoplanin in Immunohistochemistry

    Monoclon. Antib. Immunodiagn. Immunother.,35(4): 186-190, 2016(PDF)
    PDIS


  • Yamada S, Honma R, Kaneko MK, Nakamura T, Yanaka M, Saidoh N, Takagi M, Konnai S, Kato Y.*
    (*corresponding author)


    Characterization of Anti-bovine Podoplanin Monoclonal Antibody PMab-44

    Monoclon. Antib. Immunodiagn. Immunother., in press
  •  
  • Kato Y*, Ogasawara S, Oki H, Honma R, Takagi M, Fujii Y, Nakamura T, Saidoh N, Kanno H, Umetsu M, Kamata S, Kubo H, Yamada M, Sawa Y, Morita K, Harada H, Suzuki H, Kaneko MK.
    (*corresponding author)


    Novel Monoclonal Antibody LpMab-17 Developed by CasMab Technology Distinguishes Human Podoplanin from Monkey Podoplanin

    Monoclon. Antib. Immunodiagn. Immunother., 35(2): 109-116, 2016 (PDF)
    PDIS


  • Ogasawara S, Kaneko MK, Honma R, Oki H, Fujii Y, Takagi M, Suzuki H, Kato Y*
    (*corresponding author)


    Establishment of Mouse Monoclonal Antibody LpMab-13 against Human Podoplanin

    Monoclon. Antib. Immunodiagn. Immunother.,35(3):155-162, 2016(PDF)
    PDIS


  • Honma R, Fujii Y, Ogasawara S, Oki H, Konnai S, Kagawa Y, Takagi M, Kaneko MK, Kato Y * (*corresponding author)

    Critical Epitope of Anti-Rabbit Podoplanin Monoclonal Antibodies for Immunohistochemical Analysis

    Monoclon. Antib. Immunodiagn. Immunother., 35(2): 65-72, 2016(PDF)
    PDIS


  • Honma R, Fujii Y, Ogasawara S, Oki H, Liu X, Nakamura T, Kaneko MK, Takagi M, Kato Y* (*corresponding author)

    Establishment of a novel monoclonal antibody PMab-32 against rabbit podoplanin

    Monoclon. Antib. Immunodiagn. Immunother., 35(1): 41-47, 2016 (PDF)
    PDIS


  • Kaneko MK*, Abe S, Ogasawara S, Fujii Y, Yamada S, Murata T, Uchida H, Tahara H, Nishioka Y, Kato Y*.
    (*corresponding author)


    Chimeric Anti-human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain

    Monoclon. Antib. Immunodiagn. Immunother., in press


  • Ogasawara S, Kaneko MK, Price JE, Kato Y*.(*corresponding author)

    Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2.

    Hybridoma, 27(4), 259-267, 2008 (PDF)








  • *IDH関連

  • Ogasawara S, Fujii Y, Kaneko MK, Oki H, Sabit H, Nakada M, Suzuki H, Ichimura K, Komori T, Kato Y*.
    (*corresponding author)


    Establishment of Anti-Human ATRX Monoclonal Antibody AMab-6.

    Monoclon. Antib. Immunodiagn. Immunother., 35(5): 254-258, 2016 (PDF)
    PDIS


  • Hayashi A, Misumi K, Shibahara J, Kokudo N, Kato Y and Fukayama M.

    Immunohistochemistry Using Monoclonal Antibody MsMab-2 Is Useful to Detect IDH1 R132L in Intrahepatic Cholangiocarcinoma.

    Pathology international, 66(10); 578?582, 2016 (PDF)
    PDIS


  • Yamamichi A, Kasama T, Ohka F, Suzuki H, Kato A, Motomura K, Hirano M, Ranjit M, Chalise L, Kurimoto K, Kondo G, Aoki K, Kaji N, Tokeshi M, Matsubara T, Senga T, Kaneko MK, Suzuki H, Wakabayashi T, Baba Y, Kato Y, Natsume A.

    An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas

    Sci Technol Adv Mater.,17; 618-625, 2016 (PDF)
    PDIS


  • Kitago Y, Kaneko MK, Ogasawara S, Kato Y*, Takagia J*.
    (*corresponding author)

    Structural basis for multi-specific peptide recognition by the anti-IDH1/2 monoclonal antibody, MsMab-1

    Biochemical and Biophysical Research Communications, 478(3):1274-9., 2016 (PDF)
    PDIS


  • Takano S, Ishikawa E, Sakamoto N, Matsuda M, Akutsu H, Noguchi M, Kato Y, Yamamoto T, Matsumura A.

    Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas

    Brain Tumor Pathol.,33(2):107-116, 2016 (PDF)


  • Kaneko MK, Tian W, Takano S, Suzuki H, Sawa Y, Hozumi Y, Goto K, Yamazaki K, Kato Y*(*corresponding author)

    Establishment of a novel monoclonal antibody SMab-1 specific for IDH1 R132S mutation.

    Biochem Biophys Res Commun., 406(4), 608-613,2011 (pdf)(山形大学法医学との共同研究@山形大学)


  • Takano S, Tian W, Matsuda M, Yamamoto T, Ishikawa E, Kaneko MK, Yamazaki K, Kato Y, Matsumura A

    Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing

    Brain Tumor Pathology., 28(2), 115-123, 2011 (pdf)(筑波大学との共同研究@山形大学)


  • Kato Y*, Kuan CT, Chang J, Kaneko MK, Ayriss J, Piao H, Chandramohan V, Pegram C, McLendon RE, Fredman P, Mansson JE, Bigner DD.(*corresponding author)

    GMab-1, a high-affinity anti-3'-isoLM1/3',6'-isoLD1 IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice.

    Biochem Biophys Res Commun., 391(1), 750-755, 2010 (PDF)(Duke大学での仕事)


  • Kato Y*, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD(*corresponding author)

    A Monoclonal Antibody IMab-1 Specifically Recognizes IDH1R132H, the Most Common Glioma-Derived Mutation.

    Biochem Biophys Res Commun., 390(3), 547-551, 2009. (PDF)(Duke大学での仕事)


  • Takano S, Kato Y*, Yamamoto T, Kaneko MK, Ishikawa E, Tsujimoto Y, Matsuda M, Nakai K, Yanagiya R, Morita S, Tsuboi K, Matsumura A.
    (*corresponding author)

    Immunohistochemical detection of IDH1 mutation, p53 and internexin as a prognostic factor of glial tumors

    J Neurooncol. 2012 Jul;108(3):361-73(筑波大学との共同研究@山形大学)


  • Kwon MJ, Kim ST, Kwon MJ, Kong DS, Lee D, Park S, Kang SY, Song JY, Nam DH, Kato Y, Choi YL, Suh YL.

    IDH1 mutation is a favorable prognostic factor for type 2 gliomatosis cerebri

    Brain Pathol. ;22(3):307-317, 2012(韓国との共同研究@山形大学)


  • Kato Y* and Kaneko MK.
    (*corresponding author)

    Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation

    Biochem Biophys Res Commun., 433(4), 374?378, 2013 (pdf)(@山形大学)PDIS


  • Kato Y*, Natsume A, Kaneko MK.
    (*corresponding author)

    A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation

    Biochem Biophys Res Commun., 432(4):564-7, 2013 (pdf)(名古屋大学との共同研究@山形大学)PDIS


  • Kaneko MK, Ogasawara S, Kato Y*.
    (*corresponding author)

    Establishment of a novel multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.

    TJEM, 230: 103-109, 2013(@東北大学)PDIS


  • Kaneko MK, Tsujimoto Y, Hozumi Y, Goto K, Kato Y*.
    (*corresponding author)

    Novel monoclonal antibodies GMab-r1 and LMab-1 specifically recognize IDH1-R132G and IDH1-R132L mutations

    Monoclon. Antib. Immunodiagn. Immunother., 32(3), 224-228, 2013 (PDF)(山形大学解剖学との共同研究@山形大学)PDIS


  • Kaneko MK, Morita S, Tsujimoto Y, Yanagiya R, Nasu K, Sasaki H, Hozumi Y, Goto K, Natsume A, Watanabe M, Kumabe T, Takano S, Kato Y*
    (*corresponding author)

    Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations

    Biochem Biophys Res Commun., 432(1):40-5, 2013(東北大学、名古屋大学との共同研究@山形大学)PDIS


  • Ogasawara S, Kaneko MK, Tsujimoto Y, Liu X, Kato Y*.
    (*corresponding author)

    A Multi-specific Monoclonal Antibody MsMab-2 Recognizes IDH1-R132L and IDH2-R172M Mutations.

    Monoclon. Antib. Immunodiagn. Immunother., 32(6), 377-381, 2013 (pdf)(@東北大学)PDIS


  • Liu X, Kato Y*, Kaneko MK, Sugawara M, Ogasawara S, Tsujimoto Y, Naganuma Y, Yamakawa M, Tsuchiya T, Takagi M.
    (*corresponding author)

    Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.

    Cancer Med.,2(6): 803?814, 2013 (PDF)(山形大学整形外科との共同研究@東北大学)PDIS


  • Yoshikawa A, Nakada M, Watanabe T, Hayashi Y, Sabit H, Kato Y, Suzuki S, Ooi A, Sato H, Hamada JI.

    Progressive adult primary glioblastoma in the medulla oblongata with an unmethylated MGMT promoter and without an IDH mutation.

    Brain Tumor Pathol., 30(3):175-9, 2013 (pdf)(金沢大学との共同研究@山形大学)


  • Kaneko M, Liu X, Oki H, Ogasawara S, Nakamura T, Saidoh N, Tsujimoto Y, Matsuyama Y, Uruno A, Sugawara M, Tsuchiya T, Yamakawa M, Yamamoto M, Takagi M, Kato Y.*
    (*corresponding author)

    IDH2 mutation is frequently observed in giant cell tumor of bone.

    Cancer Sci.,105(6),744-8,2014 (医化学、山形大学整形外科との共同研究@東北大学)PDIS


  • Moriya K, Kaneko MK, Liu X, Hosaka M, Fujishima F, Watanabe M, Ogasawara S, Sakuma J, Sasahara Y, Kure S, Kato Y*
    (*corresponding author)

    IDH2 and TP53 mutations are correlated with gliomagenesis in a patient with Maffucci syndrome.

    Cancer Sci., 105(3),359-362,2014(小児科、整形外科との共同研究@東北大学)PDIS


  • Ohka F, Ito M, Ranjit M, Senga T, Motomura A, Motomura K, Saito K, Kato K, Kato Y, Wakabayashi T, Soga T, Natsume A.

    Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutaion

    Tumor Biol., 35(6):5911-20(名古屋大学、慶応大学先端研との共同研究@東北大学)PDIS


  • Sabit H, Nakada M, Furuta T, Watanabe T, Hayashi Y, Sato H, Kato Y, Hamada JI.

    Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence

    Brain Tumor Pathol., Oct;31(4):242-6. (pdf)(金沢大学との共同研究@東北大学)


  • Kato Y.*
    (*corresponding author)


    Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.

    Brain Tumor Pathol.,32(1): 3-11, 2015
    PDIS


  • Fujii Y, Ogasawara S, Oki H, Liu X, Kaneko MK, Takano S, Kato Y*
    (*corresponding author)

    A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas

    Biochem Biophys Res Commun., 466(4),733?739, 2015
    PDIS


  • Liu X, Ogasawara S, Kaneko MK, Oki H, Hozumi Y, Goto K, Takagi M, Kato Y.*
    (*corresponding author)

    A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma

    Biochem Biophys Res Commun., 459(4),636?642, 2015
    PDIS


  • Ikota H, Nobusawa S, Arai H, Kato Y, Ishizawa K, Hirose T, Yokoo H.

    Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies

    Brain Tumor Pathol., 32(4):237-44, 2015
    PDIS


  • Takano S, Kato Y, Yamamoto T, Liu X, Ishikawa E, Kaneko MK, Ogasawara S, Matsuda M, Noguchi M, Matsumura A.

    Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas.

    Brain Tumor Pathol., July 2015, Volume 32, Issue 3, pp 169-175
    PDIS








  • *その他

  • Umitsu M, Sakai K, Ogasawara S, Kaneko MK, Asaki R, Tamura-Kawakami K, Kato Y, Matsumoto K, Takagi J.

    Probing conformational and functional states of human hepatocyte growth factor by a panel of monoclonal antibodies

    Scientific Reports,6, Article number: 33149 (PDF)
    PDIS


  • Maekawa N, Konnai S, Okagawa T, Nishimori A, Ikebuchi R, Izumi Y, Takagi S, Kagawa Y, Nakajima C, Suzuki Y, Kato Y, Murata S, Ohashi K.

    Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers

    PLoS ONE; 11(6):e0157176, 2016 (PDF)
    PDIS


  • Yamanaka M, Kato Y, Angata T, Narimatsu H.

    Deletion polymorphism of SIGLEC14 and its functional implications.

    Glycobiology, 19(8):841-6, 2009. (PDF)


  • Hayatsu N, Kaneko MK, Mishima K, Nishikawa R, Matsutani M, Price JE, Kato Y*(*corresponding author)

    Podocalyxin expression in malignant astrocytic tumors

    Biochem Biophys Res Commun. 374(2):394-8, 2008


  • Kato Y*, Hayatsu N, Kaneko MK, Ogasawara S, Hamano T, Takahashi S, Nishikawa R, Matsutani M, Mishima K, Narimatsu H.(*corresponding author)

    Increased expression of highly sulfated keratan sulfate synthesized in malignant astrocytic tumors.

    Biochem Biophys Res Commun., 369(4):1041-1046, 2008


  • Hayatsu N, Ogasawara S, Kaneko MK, Kato Y*, Narimatsu H.(*corresponding author)

    Expression of highly sulfated keratan sulfate synthesized in human glioblastoma cells.

    Biochem Biophys Res Commun, 368, 217-222, 2008


  • Hasegawa Y, Kato Y* (double first), Kaneko MK, Ogasawara S, Shimazu M, Tanabe M, Kawachi S, Obara H, Shinoda M, Kitagawa Y, Narimatsu H, Kitajima M.(*corresponding author)

    Neutralization of blood group A-antigen by a novel anti-A antibody: overcoming ABO-incompatible solid organ transplantation.

    Transplantation. 85(3):378-385, 2008


  • Liu H, Kato Y, Erzinger SA, Kiriakova GM, Qian Y, Palmieri D, Steeg PS, Price JE.

    The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model.

    BMC Cancer.;12(1):583. [Epub ahead of print], on line (pdf)(@MDアンダーソン癌センター)


  • Motomura K, Natsume A, Watanabe R, Ito I, Kato Y, Momota H, Nishikawa R, Mishima K, Nakasu Y, Abe T, Namba H, Nakazato Y, Tashiro H, Takeuchi I, Mori T, Wakabayash T.

    Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas with integrated genomic and epigenetic profiles

    Cancer Sci.,103(10):1871-9., 2012 (pdf)(名古屋大学との共同研究@山形大学)